Viz.ai has entered a collaboration with Johnson & Johnson to expand access in the United States to software designed to help detect chronic subdural hematoma and support treatment coordination.

The companies said the agreement will focus on wider hospital adoption of Viz.ai’s Subdural Hemorrhage software, which is used for automated detection, labelling and quantification of subdural collections on imaging scans. Chronic subdural hematoma is a build-up of blood on the brain’s surface, most commonly affecting older adults.

Financial terms of the collaboration were not disclosed. Neither company said whether the arrangement is exclusive.

Viz.ai said the software includes FDA 510(k)-cleared algorithms for detection of subdural hemorrhage. The platform also includes its Viz Assist tool, which summarises patient chart information to help clinicians review imaging findings alongside medical history, medications and prior notes.

The companies said the collaboration is intended to help hospitals identify patients with suspected chronic subdural hematoma earlier and coordinate care pathways from diagnosis through follow-up.

Treatment options for chronic subdural hematoma have expanded in recent years, including growing use of middle meningeal artery embolization, a minimally invasive procedure aimed at reducing recurrence. Demand for faster diagnosis and referral has increased as hospitals evaluate which patients may benefit from surgery, embolization or monitoring.

Chris Mansi, chief executive officer and co-founder of Viz.ai, said: “By collaborating with Johnson & Johnson, we are expanding access to AI-powered detection and coordination tools, including Viz Assist, that may help clinical teams identify patients earlier, align multidisciplinary care, and ultimately support better outcomes for patients undergoing treatment for cSDH.”

Johnson & Johnson was referenced in the announcement as part of a broader neurovascular commercial effort, though no executive from the company was quoted. Further details on rollout timing or the number of hospitals targeted were not provided.

The agreement highlights continued interest from medtech and pharmaceutical groups in software that can support imaging review, workflow management and patient selection in specialist care settings. Neurology and stroke care have been among the earliest areas of adoption for such tools, particularly where speed of treatment decisions can affect outcomes.

Viz.ai said its technology is deployed in around 2,000 hospitals in the United States. The company has previously focused on stroke workflow tools before expanding into broader neurological and cardiovascular uses.

For Johnson & Johnson, the move adds software support capabilities to an area where device-based neurovascular treatment options are expanding.